University of South Florida

Digital Commons @ University of South Florida
Graduate Theses and Dissertations

Graduate School

March 2020

Synthesis of a Targeted pH Responsive Nanoparticle for
Controlled Release of Actinomycin D
Alejandro Jesus Gonzalez
University of South Florida

Follow this and additional works at: https://digitalcommons.usf.edu/etd
Part of the Medicinal Chemistry and Pharmaceutics Commons, and the Nanoscience and
Nanotechnology Commons

Scholar Commons Citation
Gonzalez, Alejandro Jesus, "Synthesis of a Targeted pH Responsive Nanoparticle for Controlled Release
of Actinomycin D" (2020). Graduate Theses and Dissertations.
https://digitalcommons.usf.edu/etd/8935

This Thesis is brought to you for free and open access by the Graduate School at Digital Commons @ University of
South Florida. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized
administrator of Digital Commons @ University of South Florida. For more information, please contact
scholarcommons@usf.edu.

Synthesis of Novel pH Responsive Nanoparticle for Controlled Release of Actinomycin D

by

Alejandro Jesus Gonzalez

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science in Pharmaceutical Nanotechnology
Department of Pharmaceutical Sciences
Taneja College of Pharmacy
University of South Florida

Major Professor: Shyam Mohapatra, Ph.D.
Subhra Mohapatra, Ph.D.
Eleni Markoutsa, Ph.D.

Date of Approval:
March 20, 2020

Keywords: Chitosan-Terephalaldehyde (CS-TPA), Actinomycin D (ACD), Tumor
Microenvironment (TME), Cancer Stem Cells (CSC), Acetazolamide (ATZ)
Copyright © 2020, Alejandro Jesus Gonzalez

ACKNOWLEDGEMENTS
I wish to thank Mohapatra Lab for stimulated the continual potential of nanotechnology on
the future of medicine. Special regards to each member of the laboratory who has assisted me on
obtaining a versatile skillset with an emphasis on good laboratory practice. I want to give special
thanks to Dr. Eleni Markoutsa for her excellent guidance of showing me to properly thinking of a
scientist. Likewise, I wish to thank Dr. Ryan Green and Dr. Mark Howell on giving me valuable
insight and for the future direction of this project.

TABLES OF CONTENTS
LIST OF FIGURES ....................................................................................................................... iii
ABSTRACT.................................................................................................................................... v
CHAPTER 1: INTRODUCTION ................................................................................................... 1
1.1: Lung Cancer ................................................................................................................. 1
1.2: Current Treatments of Lung Cancer ............................................................................ 2
1.3: Drug Resistance ........................................................................................................... 2
1.4: Cancer Stem Cells (CSCs) ........................................................................................... 3
1.5: Opportunity for Nanotechnology ................................................................................. 4
1.6: Relationship of TME and CSC .................................................................................... 6
1.7: Relationship between Hypoxia and Acidosis .............................................................. 7
1.7.1: Hypoxia ......................................................................................................... 8
1.7.2: Acidosis ........................................................................................................ 8
1.7.3: Carbonic Anhydrase IX (CA IX) .................................................................. 9
1.8: Hypothesis/Aims.......................................................................................................... 9
CHAPTER 2: MATERIALS & METHODS ................................................................................ 10
2.1 Synthesis of pH- Responsive Nanoparticle................................................................. 10
2.1.1: Component of pH- Responsive CS-TPA Nanoparticle .............................. 10
2.1.2: Synthetic Protocol of CS-TPA.................................................................... 11
2.1.3: ACD Loaded CS-TPA (LCS-TPA) nanoparticles ...................................... 11
2.2: Qualitative Evaluation of LCS-TPA pH Response.................................................... 12
2.2.1: Size Distribution Analysis .......................................................................... 12
2.2.2: TEM Analysis ............................................................................................. 13
2.3: Quantitative Evaluation of pH Response of CS-TPA................................................ 14
2.3.1: In-Vitro Encapsulation of LCS-TPA .......................................................... 14
2.3.2: In-Vitro Release of LCS-TPA .................................................................... 14
2.4: Conjugation of CA-IX Inhibitor ................................................................................ 15
2.4.1: Preparation of Targeting Moiety, AZT ....................................................... 15
2.4.2: Linking of CS-TPA & AZT ........................................................................ 16
2.4.3: NHS Reaction with CS-TPA ...................................................................... 17
2.4.4 Thiolation of AZT ........................................................................................ 18
2.4.5 AZT-SH Conjugation to CS-TPA................................................................ 18
2.5 Conjugation Efficiency via TNBSA Assay .................................................... 19
2.6 Nuclear Magnetic Resonance (NMR) ............................................................. 19
2.7 Fourier Transform Infrared Spectroscopy (FT-IR) ......................................... 20
2.8 Statistical Analysis ...................................................................................................... 20
i

CHAPTER 3: RESULTS & DISCUSSION ................................................................................. 21
3.1: CS-TPA Design ......................................................................................................... 21
3.2 Size Stability and Zeta Potential ................................................................................. 21
3.3 Qualitative Analysis of pH Response ......................................................................... 22
3.3.1 Size Distribution Analysis of pH Response ................................................. 22
3.3.2 TEM Analysis of pH Response.................................................................... 23
3.4 Quantitative Analysis of pH Response ....................................................................... 23
3.4.1 In-Vitro Encapsulation of ACD ................................................................... 23
3.4.2 In-Vitro Release of ACD ............................................................................. 24
3.5 Conjugation Efficiency ............................................................................................... 25
3.6 1H Nuclear Magnetic Resonance Analysis ................................................................. 25
3.7 FT-IR Analysis............................................................................................................ 28
CHAPTER 4: CONCLUSION & FUTURE DIRECTION .......................................................... 30
4.1 Conclusion .................................................................................................................. 30
4.2 Future Direction .......................................................................................................... 30
REFERENCES ............................................................................................................................. 31

ii

LIST OF FIGURES

Figure 1: (A)3D tumoroids LLC & A549 (B) Flow cytometry of ALDH activity in CSC (blue
region) (C)ACD reduction of ALDH activity of CSC in Scaffold model This figure is
adapted from Green et al.15 ............................................................................................ 4
Figure 2: General Schematic of TME. This figure was adapted via Biorender. ............................. 7
Figure 3: CS-TPA Reaction Scheme. ........................................................................................... 10
Figure 4: Schematic of ACD loaded CS-TPA Fabrication. .......................................................... 12
Figure 5: Experimental design of size distribution and TEM studies. .......................................... 13
Figure 6: LCS-TPA Pellet............................................................................................................. 14
Figure 7: LCS-TPA pellet dissociation in acidic environment ..................................................... 14
Figure 8: Preparation of AZT ....................................................................................................... 15
Figure 9: Structure of NHS- PEG-MAL ....................................................................................... 16
Figure 10: CS-TPA Surface Conjugation ..................................................................................... 17
Figure 11: Thiolation of AZT ....................................................................................................... 18
Figure 12: Schematic of CS-TPA-AZT ........................................................................................ 18
Figure 13: General Equation of % available amines .................................................................... 19
Figure 14: pH Responsive Design ................................................................................................ 21
Figure 15: (A) Size distribution time course study over the course of 72 hours (B) Zeta potential
measurement averaged over the course of 72 hours shows overall positive charge. ... 21
Figure 16: (A) DLS Analysis of pH Response (B) TEM Analysis of pH Response .................... 22
Figure 17: (A) ACD Standard (B) ACD % Encapsulation (C) Encapsulation Equation.............. 23
Figure 18: % Release of ACD ...................................................................................................... 24
iii

Figure 19: Conjugation Efficiency of CS-TPA AZT .................................................................... 25
Figure 20: (A) AZT exposure of free amine (∂7.52ppm (SOONH2) & ∂7.22 NH2), (B) AZT-SH
hydrocarbon extension(∂ 2.2-2.5ppm), (C)CS-TPA-PEG (∂7.8ppm MAL peak) ....... 27
Figure 21: CS-TPA-AZT (∂7.62ppm AZT sulfonamide peak) .................................................... 28
Figure 22: (A) CS-PEG-AZT (characteristic AZT 2900cm-1), (B) AZT (Characteristic 2900cm-1
peak), (C) CS (Amine peaks of 3200cm-1), (D) CS-TPA-PEG (reduction of amine
transmittance peak of 3200cm-1) .................................................................................. 29

iv

ABSTRACT
Out of all cancer diagnoses, lung cancer has the highest mortality in both sexes making it the
leading cause of cancer deaths. Current therapeutic and clinical methods fail to successfully treat
the disease, contributed to the development of multi-drug resistance (MDR). Hence, new therapies
are needed that can exploit the tumor microenvironment (TME) to target Cancer Stem Cells (CSC).
CSCs constitute a key population of the TME, promoting hypoxia, low intracellular pH, and
angiogenesis. Actinomycin D (ACD) is a potent CSC inhibitor, but due to its high toxicity and
lack of specificity towards cancer cells there is a need targeted nano-delivery system. This project
focuses on the synthesis of a novel pH-responsive nanoparticle for the controlled release of ACD.
Chitosan (CS) nanoparticles crosslinked with Terephalaldehyde (TPA) form a stable Schiff-base
at neutral pH. CS-TPA form relatively homogenous nanoparticles in aqueous phase with a Zaverage size of 195nm±1.6. Since acidosis and hypoxia are coupled within the TME due to high
Carbonic Anhydrase IX (CA-IX) expression, acetazolamide (AZT), a CA-IX inhibitor, is
conjugated on to the surface of CS-TPA nanoparticles as a targeting moiety to potentially enhance
solid tumor penetrance. This study demonstrates successful synthesis, characterization, and
imaging of CS-TPA and CS-TPA-AZT nanoparticles along with in-vitro analysis of pH responsive
release with ACD-loaded CS-TPA nanoparticles.

v

CHAPTER 1: INTRODUCTION

1.1: Lung Cancer
According to the International Agency of Cancer Research, the number of new cancer
cases is expected to increase significantly in the coming years. GLOBOCAN 2018 predicted an
estimated 9 million individuals will die from some form of cancer, with the majority of deaths
being due to lung cancer1. The American Cancer Society (ACS) iterated that there are nearly 1.8
million new lung cancer cases a year with estimated 5-year survival depending on the stage and
regional differences2. There exist several treatment methods for lung cancer such as surgery,
radiation therapy, radio frequency ablation, molecular targeted therapy, immunotherapy, etc.
Unfortunately, none of these therapies are fully effective and fail to reduce the incidence and
mortality rate of lung cancer. Lung cancer is divided into two major categories Non-Small Cell
Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), with each type having a variety of
subtypes that differentiate distinctly from one another. NSCLC represents nearly 90% of lung
cancer diagnosis in both males and females; several risk factors like smoking, genetic
predisposition, or geographical air quality/pollution enabling such a high volume of the regional
population to be effected.3–5. These statistics demonstrate the inadequacy of current lung cancer
treatment methods leading to the need for a new approach to treat this lethal disease.
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1.2: Current Treatments of Lung Cancer
The ACS reports a variety of treatment methods for lung cancer in correspondence to the
stage of development. Diagnosis is the most critical step prior to the beginning of treatment, the
evidence presents that nearly 70% of patients are victims of late stage cancer6. Early stages resort
to surgery and radiofrequency ablation, while later stages tend to utilize riskier therapeutic
methods such as radiation therapy and chemotherapy. Molecular targeted therapies and immune
therapies tend to specifically act on the highly expressed EGFR, ALK, or BRAF pathways these
are commonly affiliated cell signaling proteins associated with malignant cancer drug resistant
characteristics. Unfortunately, not all lung cancer types express the same phenotypic pathways
enabling multiple drug resistance mechanism presenting a challenge for the current therapeutic
treatments to act effectively2,7,8.

1.3: Drug Resistance
Inactivation of anti-cancer drugs is enabled through drug resistance, many of these
therapies rely on specific metabolic pathways to increase efficacy. Unfortunately, cancer has an
adaptive ability to decrease these drug activating pathways9. Tumoral evolution allowing drug
resistance is due to intratumoral heterogeneity. NSCLC exhibit a high degree of somatic cell
mutation from observed intratumoral heterogeneity that enables the development of drug
resistance pathways in lung cancer treatment. There have been some correlation that heterogeneity
and cancer stemness operate synergistically allowing cancer to balance between stages of
quiescence, proliferation, and regeneration3,10–12. The occurrence of tumor heterogeneity is due to
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cancer stem cells (CSC) or cancer initiating cell (CIC), which are present deep within solid tumor
cores13.
1.4: Cancer Stem Cells (CSCs)
As aforementioned CSC are active cells that lie deep within a solid tumor core, which are
present in many cancers (i.e. lung cancer, colorectal cancer, pancreatic, etc.). The role of CSCs in
many proliferative, quiescence, and regenerative pathways of cancer has gathered the attention of
many researchers and clinicians as a potential need to target these species of stem cells (SC)13.
Although, there is a clear malignant difference between CSC and normal SC, the main property
that coincides with the two is long term self-renewal. A Common CSC regulation pathway
involves the upregulation of Wnt/β-Catenin, which is responsible for the dedifferentiation of both
neighboring cancer cells and within cancer cells, causing changes in phenotypic responses against
anti-cancer drugs13. This is a major reason why current therapies fail to function properly due to
the inability to penetrate the solid tumor allowing CSCs to develop adaptive drug resistant
mechanisms via cancer evolution.13–15.
With an intent to target CSCs, our lab recently demonstrated that actinomycin D (ACD), a
potent anti-CSC agent acted synergistically when administered in combination with telmisartan
(TEL), an anti-fibrotic agent and inhibited invitro as well as in vivo tumor growth15. The study
aimed to mimic the tumor microenvironment (TME) using 3D- fibrous scaffold model to grow
‘tumoroids’ that increased CSC development in-vitro in Lewis Lung Carcinoma (LLC) and human
lung carcinoma cells (A549) (Figure 1A)15. The Presence of CSCs in tumoroids was verified using
aldehyde dehydrogenase (ALDH) enzymatic activity that is upregulated when CSCs are present
within a solid tumor core (Figure 1B)15. Finally, the experiment concluded the synergistic
combination of ACD and TEL inhibited CSC growth and induced CSC death(Figure 1C)15.
3

Although ACD proves effective in killing CSCs there remains a major issue with toxicity
and lack of targeting ability to reach the solid tumor core. Due to these inadequate components,
ACD cannot properly act to induce CSC death, instead the same obstacle of drug resistance
remains. This exemplifies the need to create a system that can enhance the targeting of ACD
toward the tumor core to kill CSCs.

A

B

C

Figure 1: (A)3D tumoroids LLC & A549 (B) Flow cytometry of ALDH activity in CSC (blue region)
(C)ACD reduction of ALDH activity of CSC in Scaffold model This figure is adapted from Green et
al.15

1.5: Opportunity for Nanotechnology
Nanotechnology can prove valuable in optimizing the effectiveness of ACD against CSCs.
Recently there has been much traction gathered by nanomedicine in the treatment of cancer,
diabetes, bacterial infections, cardiovascular disease, etc16,17. There is a prospect in using
nanotechnology for lung cancer due to various formulations that can be developed like liposomal,
polymeric, and inorganic18.
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Liposomal nanoparticles are synthetic vesicle structures using amphipathic lipids that form
a bilayer. These structures have great biocompatibility and safety profiles that allow them to be
suitable candidates for drug delivery. When synthesized their surface can be modified in various
ways conjugating proteins, anti-bodies, fluorophores, etc. A notable example is the FDA approved
Doxorubicin (DOX) loaded Liposomal nanocarrier18,19.
Polymeric Nanoparticles utilized polymers using emulsions, probe sonication, or
precipitation methods to synthesize self- assembling co-polymers. These systems can be modified
to have varying hydrophobicity and hydrophilicity. Many times, encapsulating hydrophobic drugs
within hydrophilic nanoparticles proves an effective way to deliver drugs with higher efficacy.
Similarly, to liposomes their surfaces can also be conjugated for more improved targeting18,20.
Inorganic nanoparticles have a been used for a variety of theragnostic applications; drug
delivery, biosensing, imaging, and even cancer therapy18,21,22. One example of inorganic
formulation that has shown promise in recent decades is gold (Au) Nanoparticles. This formulation
has relatively high biocompatibility and multifunctional applications. Although, these systems are
inorganic in nature their surfaces can be conjugated with bioorganic materials for more improved
targeting like the preceding formulations. Unlike the other methods mentioned, inorganic
nanomaterials can be more sensitive to external stimuli like thermal, light, and ultrasound18,23–26.
These general types of formulations may help better understand methods to develop more
improved and optimal systems to address challenges for drug delivery to lung cancer. The greatest
quality of most formulations is the versatility to target specific stimulus to release a drug or allow
entry into tumor cells. This begs the question as to what physiological stimulus allows entry
through solid tumors to effectively kill CSCs. The answer lies in the exploitation of the TME which
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allows CSCs to effectively utilize drug resistant pathways and prevent the entry of xenobiotics into
the tumor core where CSCs reside.
1.6: Relationship of TME and CSC
CSCs are a major contributor to the development of many cancer types that form solid
tumors, and especially common in the progression of lung cancer. Although, drug resistance is a
major hurdle for lung cancer treatment, how CSC develops is explicitly due to tumor
heterogeneity27. As aforementioned, CSCs have the innate characteristic to express distinct
phenotypes primarily due to the various cell types that are incorporated into a solid tumors TME.
Much research has shown that intratumor heterogeneity allows for changes in cancer metabolism,
increased mutations & differentiation, protection of CSC via drug resistant pathways3,10,13. There
should be no surprise that due to intratumor heterogeneity there will be inevitable changes to the
microenvironment surrounding a tumor in comparison to normal tissue. Much cancer research has
emphasized the importance of the TME and its companionship with CSCs to act as a modulator of
drug resistance28. Hence, understanding the TME will give necessary insights as to how to develop
a nanoformulation that can target and exploit its specific qualities.
The TME consists of extracellular matrix (ECM), stem cells, mesenchymal stem cells,
adipocytes, pericytes, blood, and immune cells. Due to these cell types it is postulated that
proliferation and survival are not solely due to cancer cells, but the interaction between cells that
surround the tumor cells giving rise to the TME. The modulatory aspect of the TME allows for
cancer cell maintenance and non-autonomous drug resistance through the various mechanisms,
including hypoxia, extracellular acidity, increased lactic acid metabolism, changes in immune
populations, and cancer associated fibroblast (CAF)29,30. Exploiting these non-autonomous
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components that occur in conjunction with TME may prove advantageous for incorporating a
targeted approach of a nano carrier system.
1.7: Relationship between Hypoxia and Acidosis
The TME has an implicit role in the progression and survival of lung cancer, which is
attributed to the non-autonomous drug resistant mechanisms29. Figure 2 provides an illustration of
some of the general non-autonomous mechanisms, such as hypoxia, acidity, enzymatic changes in
activity, and decreased reactive oxygen species (ROS)31. Fortunately, many of these TME

Figure 2: General Schematic of TME. This figure was adapted via Biorender.

characteristics are coupled with one another such as hypoxia and acidosis which have an inclusive
relationship where one can cause the other and vice versa32. Hence, the aim of this study is to
develop a novel nanomaterial that will potentially act to exploit hypoxia and acidosis.
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1.7.1: Hypoxia
Oxygen is a major biological necessity in many aerobic metabolic pathways, which enable
normal tissue function. Tumors manage to adapt effectively at significantly lower levels of oxygen
in comparison to normal tissue. Hypoxia, a major feature in the development of solid tumor
progression in lung cancer is characterized when physiological oxygen levels reach below
normoxia levels (≤2.03-3.04KPa)5. Many studies have connected hypoxia to enable lung cancer
drug resistance, hence understanding the fundamental biological phenomenon that make up
hypoxia is necessary. HIF-1α is the transcription factor associated with hypoxia progression, which
is fairly easily identifiable5. Targeting hypoxia to release a drug load has been utilized in
nanomaterial development, for example, recent study utilized a Carbonic Anhydrase IX (CA IX)
inhibitor, acetazolamide, as a targeting moiety to demonstrate successful hypoxic tumor
penetrance33.
1.7.2: Acidosis
Hypoxia has a significant role in the TME, there also exists an established relationship with
acidosis and hypoxia. Due to low oxygen availability in the tumor there is an upregulation of
anaerobic metabolism to allow tumors proliferation and growth. Some metabolic pathways involve
the overproduction of lactic acid and upregulation of glycolysis, which allows for continuous
energy production for cancer cells34. Due to the expression of the transcription factor, HIF-1α, a
cyclic regulation between hypoxia and extracellular acidosis allows for tumor cells to act out
common drug resistant pathways including, drug efflux, resistance to mitochondrial damage,
autophagy, and changes in p53 pathways32. Typically, in normal tissues experiencing such low
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acidity will die, but hypoxic tumors tend to express a glycoprotein, CA IX, which act as a bridge
of modulation between hypoxia and acidosis34.
1.7.3: Carbonic Anhydrase IX (CA IX)
In understanding the relationship between hypoxia and acidosis it is established that
hypoxic tumors express a metalloenzyme glycoprotein, CA IX. This enzyme plays an important
role in utilizing the bicarbonate buffer system to maintain acid-base balance for a variety of
biological processes34. Due to tumors upregulation of glycolytic pathways there is inevitable
production of CO2 in the intracellular space, along with the overproduction of lactic acid producing
an excess of proton build up within the cell. Using a bicarbonate transport system CA IX mediates
a cyclic regulation of protons and carbon dioxide by the continuous decomposition of carbonic
acid, which enables tumor cells to thrive causing a cascade of phenotypic changes enabling drug
resistance and differentiation34. With this continual pH regulation occurring on the surface of
tumor cells angiogenesis can occur due to intratumorally heterogeneity recruiting more blood
vessels from an extracellular environment allowing for growth, metastasis, and proliferation34.

1.8: Hypothesis/Aims
Based on the established characteristics of the TME the development of a nanocarrier that
exploits these properties can be formulated to enable the controlled release of ACD. The aims of
the study are discussed as follows (1) Synthesis of a pH- responsive nanoparticle incorporating
ACD (2) In-vitro evaluation of encapsulation and release of ACD, and (3) Conjugation and
characterization of the CA IX inhibitor, acetazolamide, onto the surface of pH-responsive
nanoparticle.
9

CHAPTER 2: MATERIALS & METHODS
2.1 Synthesis of pH- Responsive Nanoparticle

2.1.1: Component of pH- Responsive CS-TPA Nanoparticle
Low molecular weight (10Kda) Chitosan (CS) (TransGenex Nanobiotech Inc) is the
polymer of choice to be crosslinked by terephalaldehyde (TPA) (Sigma Aldrich). CS was chosen
due to its high density of reactive amines that can be conjugated and crosslinked, also the
oligosaccharide has a very low toxicity profile and good biodegradability and biocompatibility.
TPA is an aromatic aldehyde that can form stable Schiff base at neutral pH when reacted with
amines in basic conditions. Figure 3 shows the general reaction scheme of CS-TPA nanoparticle
formation.

Figure 3: CS-TPA Reaction Scheme.
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2.1.2: Synthetic Protocol of CS-TPA
Before beginning the reaction two separate solution of 1mg/ml CS was dissolve in nano
pure sterile H2O and 10mg/ml TPA was dissolved in tetrahydrofuran (THF). The pH of the CS
solution was measured using Fischer brand pH paper and was found to be 5 when dissolved in
H2O, this is due to protonation of free amines in the aqueous phase. From the TPA stock solution
an aliquot of 200ul was added to the CS solution and vortexed until fully miscible. The pH of the
reaction solution was measured again to assure that pH remained at 5. Immediately upon
measuring aliquots of 0.1M NaOH were added to a final concentration of 17mM, and
ultrasonicated aggressively with a 3mm probe sonicator for 30mins. Completion of the reaction
was indicated when pH reached 7, the CS-TPA nanoparticle solution was put on dialysis
(molecular weight cut off 3500Da) against 1% Phosphate Buffer (pH 7) for 6 hours to remove any
unreacted TPA and excess hydroxide ions that may interfere with Schiff base bond. The CS-TPA
solution was then stored in 4oC for the examination of size stability, transmission electron
microscopy (TEM), and in-vitro assessment with ACD.
2.1.3: ACD Loaded CS-TPA (LCS-TPA) nanoparticles
To initiate the loading of ACD a 10mg/ml Stock was prepared in DMSO to produce a
bright orange-red solution. The same protocol as presented in section 2.1.1. was followed with
the addition of several ACD concentrations (10ug/ml, 20ug/ml, and 30ug/ml) prior to the vortexing
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step of the reaction mixture. Upon vortexing the process was completed as described above. Figure
4 represents the fabrication process of ACD loaded CS-TPA.

Figure 4: Schematic of ACD loaded CS-TPA Fabrication.

2.2: Qualitative Evaluation of LCS-TPA pH Response

2.2.1: Size Distribution Analysis
Malvern Zetasizer was used to measure both size distribution and zeta potential of ACD
loaded CS-TPA. The loaded CS-TPA particles were then exposed to a pH 6 environment
throughout 72 hours and size distribution was measured vs. neutral pH nanoparticles to observe
the relative change in size distribution.
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2.2.2: TEM Analysis
All CS-TPA (loaded and unloaded) images were taken using Joel 1400 Transmission
Electron Microscope (TEM). Images were taken in two separate experiments, first a control image
at x150K magnification of CS-TPA nanoparticles. The next experiment involved placing the CSTPA nanoparticles in a distinct acidic environment (pH: 7,6,5) in 1:5 solution using HCl to adjust
to the desired pH. Images were taken of CS-TPA to observe the physical dissociation of

Figure 5: Experimental design of size distribution and TEM studies.

nanoparticles at x150K magnification. Figure 6 represents the full experimental design of both size
distribution and TEM studies.
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2.3: Quantitative Evaluation of pH Response of CS-TPA
2.3.1: In-Vitro Encapsulation of LCS-TPA
Encapsulation Efficiency of ACD within CS-TPA nanoparticles was evaluated using the
ultracentrifugation method. The LCS-TPA nanoparticles with varying concentrations of ACD
were prepared in triplicate for a 1:10 dilution in nano-pure sterile H2O. Upon preparation the
diluted dispersions were then transferred to Beckman
polypropylene tubes. After transfer the tubes were loaded
into the Beckman coulter TLA rotor to be prepared for
ultracentrifugation. Beckman Coulter Optima MAX-XP
was the ultracentrifuge used for the study, the method was
set to 4oC at 120,000RPM for 2 hours. After the completion Figure 6: LCS-TPA Pellet
a yellow pellet was observed indicating LCS-TPA nanoparticles (Figure6). The pellet was then
dispersed in H2O for UV-Vis measurement at λmax= 440nm based on prepared the ACD standard
curve.
2.3.2: In-Vitro Release of LCS-TPA
Percent release was accessed using the LCS-TPA with the highest encapsulation efficiency.
LCS-TPA was placed in varying tubes with specific pH (7,6, and 5) in a 1:5 dilution of nanoparticle
to H2O. The samples were prepared in
triplicate for each condition, the samples
were vortexed and varying time points
were accessed (30min, 1hr, 2hr, and 6hrs)
using the ultracentrifugation method as

Figure 7: LCS-TPA pellet dissociation in acidic
environment
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done in section 2.3.1. The supernatant was collected and evaluated via UV-Vis at λmax=440nm.
Percent release was calculated based on prepared the ACD standard curve as done in section 2.3.1.
Figure 8 shows the disappearance of LCS-TPA pellet which indicated nanoparticle dissociation
and release of drug in the supernatant.

2.4: Conjugation of CA-IX Inhibitor
2.4.1: Preparation of Targeting Moiety, AZT
Acetazolamide, a known CA IX inhibitor, was purchased from ThermoFischer Scientific.
In order to prepare for conjugation onto the surface of CS-TPA preparation of acetazolamide
requires an acid catalyzed deacetylation reaction to expose a more reactive free amine for more
feasible and quick reactions. 3g of acetazolamide (13.5mmol) is to be refluxed at 110oC in 3M
HCl (25ml) for 4hours (Figure 8). The reaction mixture was neutralized in 4M NaOH (18ml) to
then be extracted with Ethyl Acetate (EtOAc). The organic layer was washed once with brine and
then dried over NaSO4. The organic layer was then filtered and concentrated in-vacuo to obtain a
white crystalline powder with a 90% yield (2.18g). The obtained product, AZT, was verified via
1

H NMR.

Figure 8: Preparation of AZT
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2.4.2: Linking of CS-TPA & AZT
Conjugation of AZT onto the surface of CS-TPA suggest the need for a biodegradable and
biocompatible material. Polyethylene glycol (PEG) is a commonly used linker for many
conjugation reactions. For the purposes of this experiment it was decided to use N-Hydroxy
succinimide- PEG- Maleimide (NHS-PEG-MAL) due to the distinctly reactive capabilities of NHS
and MAL. (Figure 9).

Figure 9: Structure of NHS- PEG-MAL

The NHS- ester is reactive with amines which presents it to be a good candidate for the surface
modification of CS-TPA. The MAL end of the linker is reactive towards thiol groups which
requires an additional derivation of AZT. Due to the deacetylation of a reactive amine, which has
been exposed allows the use of Traut’s Reagent (2-iminothiolane) that effectively thiolates amines.
The reaction is sensitive to oxidative conditions but once reacted with MAL group the covalent
bond provides a strong stable conjugation. Hence, this linking reaction requires two separates
‘click’ chemistry reactions to fully conjugate AZT to CS-TPA.
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2.4.3: NHS Reaction with CS-TPA
Upon synthesis of CS TPA nanoparticles at pH 7 a TNBSA assay was done to determine
the molar quantity of available amines on CS. The assay determined there was an estimated 77mM
amines to undergo the reaction, therefore 1ml of the CS-TPA nanoparticle solution was directly
added to a round bottom flask and stirred slowly. NHS-PEG-MAL was calculated to react with
half the molar quantity, 38.5mM, of available amines to allow full conjugation of PEG onto the
surface of CS-TPA. The reaction was maintained at pH 7 at RT for 2 hours (Figure 10). After
completion of the reaction an aliquot was collected for characterization via NMR, FTIR, and TEM.

Figure 10: CS-TPA Surface Conjugation
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2.4.4 Thiolation of AZT
During the CS-TPA conjugation in a separate round bottom flask AZT (15mg) was
dispersed in pH 7 0.1M phosphate buffer. AZT was stirred and left under argon for two hours prior
to beginning the thiolation reaction to assure inert conditions. Traut’s reagent was dissolved in 1ml
0.1M phosphate buffer at 1:1 with AZT reactive amine. The Traut’s solution was slowly added to
the AZT dispersion slowly. The reaction progression was indicative was AZT was fully soluble in
the phosphate buffer for 2 hours at room temperature (Figure 11). Upon completion of the reaction
an aliquot was collected for characterization via NMR, FT-IR, and TEM.

Figure 11: Thiolation of AZT

2.4.5 AZT-SH Conjugation to CS-TPA
While the AZT-SH remained stirring in inert condition, the CS-TPA-PEG reaction was
collected in a separate vessel immediately. The CS-TPA-PEG solution was then slowly added to

Figure 12: Schematic of CS-TPA-AZT

the AZT-SH solution to assure that the thiolate product had minimal exposure to potential
18

oxidation. The reaction was left to stir slowly in 4oC overnight to allow full completion of the
reaction (Figure 12). An aliquot was taken to be characterized via NMR, FT-IR, and TEM.

2.5 Conjugation Efficiency via TNBSA Assay
Due to CS high concentration of functionable amines conjugation efficiency can be
calculated using 2,4,6- trinitro benzoic acid (TNBSA) assay, which allows for the quantification
of available amines on proteins, polymers, etc. The protocol was followed based on manufacturers
recommendations. To begin assessment a CS standard was developed using a series of
concentration (100ug-1000ug/ml). Upon completion of the CS standard unloaded CS-TPA were
assessed for available amines and compared to the standard, likewise, the final product, CS-TPAAZT, was done in the same fashion. Conjugation efficiency was then based on the %Available
Amines (figure 13) and based on the CS standard the % occupied amines would correspond to the
conjugation efficiency.

% 𝑨𝒗𝒂𝒊𝒍𝒂𝒃𝒍𝒆 𝑨𝒎𝒊𝒏𝒆𝒔 =

𝑪𝑺𝑨𝒎𝒊𝒏𝒆𝒔 − (𝑪𝑺 − 𝑻𝑷𝑨𝑨𝒎𝒊𝒏𝒆𝒔 )
𝑥10
𝑪𝑺𝑨𝒎𝒊𝒏𝒆𝒔

Figure 13: General Equation of % available amines

2.6 Nuclear Magnetic Resonance (NMR)
All products were analyzed using a Varian 400Hz instrument. Upon obtaining the
lyophilized product was dispersed in deuterated water (D2O) at 1mg/ml in specialized NMR tubes
to access 1H NMR.
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2.7 Fourier Transform Infrared Spectroscopy (FT-IR)
All products that were lyophilized were accessed in ThermoFischer solid state FT-IR to
access reaction progression and conjugation to obtain a final product.

2.8 Statistical Analysis
All data excluding NMR and FT-IR were all analyzed via standard error, standard
deviation, and t-test to access the significance and variability of the data set. The data proved
significant with precision and minimal variability. Hence the study had valid consistency and
reproducibility of the experimental study.
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CHAPTER 3: RESULTS & DISCUSSION

3.1: CS-TPA Design
The design of pH response of CS-TPA is based on the
sensitivity of the Schiff base bond towards an acidic
environment. Due to the formation of nanoparticle being base
catalyzed, the reverse reaction can be initiated via acidic
hydrolysis. Figure 14 demonstrates the design of the pH
responsive CS-TPA.
Figure 14: pH Responsive Design

3.2 Size Stability and Zeta Potential
The synthesized loaded CS-TPA was analyzed by Malvern Zetasizer for both size and
zeta potential. The results indicated that in the course of three days after synthesis (Day 0) size
A

B

Figure 15: (A) Size distribution time course study over the course of 72 hours (B) Zeta potential measurement
averaged over the course of 72 hours shows overall positive charge.
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and pH remained stable at a Z-average size of 195nm±1.6 (Figure 15A). Furthermore, it is well
established that low MW CS expresses a relative positive charge in aqueous phase due to amine
protonation giving us a consistent positive charge of 17mV (Figure 15B).

3.3 Qualitative Analysis of pH Response

3.3.1 Size Distribution Analysis of pH Response
As described previously LCS-TPA was placed in distinct pH (7, 6, 5) to access relative
size change upon exposure to an acidic environment. Results showed that in neutral pH size
remained as expected 195nm±2.3. Once exposed to pH 6 relative size change was evaluated
using the Zetasizer software observing a ΔZ-average size +200nm. pH 5 was attempted to be
analyzed but the particles fully aggregated not allowing the Zetasizer to achieve a successful
distribution, which indicated that CS-TPA fully dissociates when exposed to pH 5 (Figure 16A).
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Figure 16: (A) DLS Analysis of pH Response (B) TEM Analysis of pH Response
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3.3.2 TEM Analysis of pH Response
Analysis via TEM revealed clear images of the morphology change of the LCS-TPA
nanoparticles, which demonstrated the dissociation of Schiff Base bonds upon exposure to an
acidic environment compared to neutral pH (Figure 16B).

3.4 Quantitative Analysis of pH Response

3.4.1 In-Vitro Encapsulation of ACD
Using an ACD standard curve (Figure 17A) it was found that the free drug has a UV-Vis
absorbance range of 415-445nm with the determination of λmax=440nm. As explained
ultracentrifugation method was done and upon collection of the supernatant the determined λmax
was used to calculate % Encapsulation (Figure 17B). Results revealed 50% encapsulation with

B

A

C

Figure 17: (A) ACD Standard (B) ACD % Encapsulation (C) Encapsulation Equation

no significant change in loading using varying ACD concentrations (Figure 17C).
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3.4.2 In-Vitro Release of ACD
The release of ACD was further accessed using 30ug/ml LCS-TPA by ACD standard
curve to evaluate % release throughout a time course of up to 6 hours at various pH (Figure 18).
The results revealed at neutral pH there was nearly no release in the time course study, unlike pH
6 and 5 where the majority of drug was released at 70% and 100% post 6 hours, respectively.
The time course study also revealed that LCS-TPA exhibited burst release properties within 30
p H r e s p o n s iv e R e le a s e
100
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80
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Figure 18: % Release of ACD

mins exposed to acidic environment releasing 50% and 70% of drug was at pH 6 and 5,
respectively. After 30 mins LCS TPA exhibited controlled release by releasing roughly 10% of
ACD in the designated pH environments at time 60min and 120min. These results are indicative
of LCS-TPA drug release in response to an acidic environment as an expected aim formulated
within this study.
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3.5 Conjugation Efficiency
A TNBSA assay was performed to access the conjugation efficiency of each CS, CS-TPA,
and CS-TPA-AZT product. This was done on the basis following the CS standard and evaluated
based on occupied amines. Upon calculating the conjugation efficiency, it was found that 78% of
the amines were occupied based on the final product CS-TPA-AZT; the graphical analysis is
provided as basis for this estimation (Figure 19). Quantification of CS-TPA-AZT revealed that
nearly 78% of amines were occupied relative to the CS standard which directly corresponds to
78% conjugation efficiency. This is clear indication that the surface conjugation has, in fact,
occurred.

Figure 19: Conjugation Efficiency of CS-TPA AZT

3.6 1H Nuclear Magnetic Resonance Analysis
Upon completion of each reaction products were lyophilized to be run on a Varian 400MHz
in either deuterated H2O (D2O) or deuterated DMSO (DMSO d6). The NMR was analyzed based
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on reactants to products to assure that a reaction did progress accordingly to define characteristic
peaks. The targeting moiety AZT was the first analyzed product prior to the initialization of surface
conjugation (Figure 20A). DMSO d6 peak was standardized at 4.3ppm, acetazolamide had
characteristic peaks defined by the acetyl group (2.16ppm) and the free amine of the sulfonamide
group (7.52ppm). AZT was discovered to undergo full completion upon deacetylation exposing
the free amine (7.22ppm), this was obtained in one hundred percent purity. The thiolation of AZT
was initialized utilizing Traut’s reagent, the lyophilized product was dissolving in D2O to be
analyzed (Figure 20B). The reaction showed a disappearance in the free amine peak (7.22ppm)
and the appearance of new peaks based on the sulfhydryl group (1.3ppm) along with peaks
displayed from the hydrocarbon chain extension (2.2ppm-2.54ppm). The NMR of AZT-SH still
needs development on better purity to remove the crude peaks that appear to the reaction
progression. There is also the possibility that disulfide bonds are forming during reaction
progression due to residual oxidative species within the system. CS-TPA surface conjugation was
determined via the method as described above. First, pure NHS-PEG-MAL was characterized to
define the characteristic peaks of NHS (2.64ppm) and MAL (7.8ppm). Upon completion of the
conjugation reaction on the surface of CS-TPA is initialized by a commonly known NHS-ester
amine chemistry. It was noticed upon analysis of the CS-TPA-PEG product that the NHS-ester
group disappeared and the MAL group peak (7.8ppm) remained intact. This demonstrates a
successful conjugation on to the surface of CS-TPA (Figure 20C). Finally, AZT-SH reaction with
the MAL portion was then analyzed to evaluate the final product of CS-TPA-AZT (Figure 21).It
was noticed that the appearance of the AZT sulfonamide amine peak (7.62ppm) along with the
maintained PEG peaks (2.45ppm & 3.5ppm).
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Figure 20: (A) AZT exposure of free amine (∂7.52ppm (SOONH2) & ∂7.22 NH2), (B) AZT-SH
hydrocarbon extension(∂ 2.2-2.5ppm), (C)CS-TPA-PEG (∂7.8ppm MAL peak)
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Figure 21: CS-TPA-AZT (∂7.62ppm AZT sulfonamide peak)

3.7 FT-IR Analysis
The final method of analysis of the final product to confirm validation of CS-TPA surface
conjugation of AZT was done via FT-IR. The data presents that CS had definitive amine peaks as
shown 3200cm-1(Figure 22C). When conjugation occurred, the amines lost transmittance due to
the occupation of the amine groups. AZT is shown with a characteristic sulfonamide amine peak
at an estimated 2900cm-1(Figure 22B). When Conjugating PEG (Figure 22D) the amine peak loss
transmittance as described in the former. Finally, CS-TPA-AZT demonstrated the presence of
2900cm-1 peak from AZT and nearly complete loss of the amine signals indicative of full
conjugation of the CS-TPA nanoparticles. (Figure 22A).
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Figure 22: (A) CS-PEG-AZT (characteristic AZT 2900cm-1), (B) AZT (Characteristic 2900cm-1 peak),
(C) CS (Amine peaks of 3200cm-1), (D) CS-TPA-PEG (reduction of amine transmittance peak of
3200cm-1)
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CHAPTER 4: CONCLUSION & FUTURE DIRECTION
4.1 Conclusion
According to the established aims of the experiments a stable pH- responsive nanoparticle,
CS-TPA, was successfully synthesized which can release its payload ACD upon exposure to acidic
environment per the qualitative and quantitative in-vitro analysis of LCS-TPA. Furthermore,
conjugation of CA IX inhibitor, acetazolamide, has been executed and characterized via use of
NMR and FT-IR for potential enhancement for targeting hypoxic tumor core. Therefore, this novel
nanoparticle can then be used for targeted delivery of ACD to exploit the TME as proposed in this
study.

4.2 Future Direction
To demonstrate the effectiveness of this novel nanoformulation, the TME will be modeled
using 3D ‘Tumoroids’ of LLC and A549 cell lines as previously demonstrated by our colleagues.
Cell uptake, viability, and death will be evaluated of both ACD-Loaded CS-TPA and CS-TPAAZT to effectively demonstrate its targeted ability. Furthermore, toxicity studies will be developed
in comparison to ACD free drug to access efficacy and cytotoxicity.
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